The KLOW Peptide Stack and GLP-1 Therapy: What the Evidence Actually Shows

The short answer: KLOW is a four-peptide blend — GHK-Cu, BPC-157, TB-500, and KPV — that targets the biological collateral damage of rapid GLP-1-driven weight loss: skin laxity, gastrointestinal distress, chronic inflammation, and impaired tissue repair. The evidence base for each individual peptide is real, though still primarily preclinical. The stack as a combined formulation has not been studied in randomised controlled trials. This guide explains what is known, what is not, and what to discuss with your metabolic health physician.

If you are on semaglutide, tirzepatide, or any GLP-1 receptor agonist and you have spent time in health forums recently, you have almost certainly encountered the acronym KLOW. Peptide stacks are one of the fastest-growing conversations among patients optimising their weight loss journey — and KLOW sits at the centre of that discussion because it speaks directly to a problem GLP-1 users experience but rarely see addressed by their prescribing physician: the biological cost of losing weight faster than the body can adapt.

Rapid, drug-assisted weight loss is genuinely transformative. It is also physiologically stressful in ways that slower weight loss is not. Skin cannot retract fast enough. The gut absorbs the pharmacological brunt of GLP-1 activity. Inflammation — the very driver that made losing weight hard in the first place — does not resolve linearly as the scale moves. And collagen, which declined at roughly 1% per year before any medication was involved, does not rebuild itself simply because fat is leaving.

KLOW is being positioned — by compounding pharmacies, functional medicine clinics, and an active research community — as a solution to these downstream consequences. This guide examines that claim through a clinical lens.

What Is the KLOW Peptide Stack?

KLOW is a branded name for a compounded peptide blend containing four components in a standardised 80 mg vial, typically formulated at a 5:1:1:1 ratio:

KLOW is an evolution of the GLOW stack (which contains GHK-Cu, BPC-157, and TB-500) with KPV added to specifically address the inflammatory dimension of tissue stress. It is administered subcutaneously and is available through compounding pharmacies under physician supervision.

KLOW is not FDA-approved for the treatment of any disease. It is offered under compounding regulations and is intended for use within a medically supervised protocol. For a full picture of the current regulatory landscape around compounded peptides, see Meto's guide on FDA compounded peptides and what the 2026 policy changes mean for patients.

The Biological Problem: What Rapid GLP-1 Weight Loss Does Beneath the Surface

To understand why KLOW is generating so much interest among GLP-1 users specifically, you need to understand what happens biologically when weight loss is accelerated by pharmacotherapy.

Skin Laxity and Collagen Disruption

GLP-1 receptor agonists like semaglutide and tirzepatide produce weight loss at a rate that routinely outpaces the skin's adaptive capacity. In a peer-reviewed review published in Aesthetic Medicine, researchers noted that rapid weight reduction impairs the skin's ability to regenerate and maintain elasticity — leading to sagging, volume loss, and structural changes in the dermis, particularly in patients who are already past the collagen-decline threshold of their mid-thirties.

The mechanism is not cosmetic — it is structural. The skin relies on three load-bearing pillars: subcutaneous fat pads, a collagen-elastin matrix in the dermis, and the underlying musculature. GLP-1-driven weight loss depletes all three simultaneously. Published clinical observations describe collagen depletion and muscle loss as accelerating the ageing process in ways that manifest within months of initiating therapy.

Gastrointestinal Burden

GLP-1 receptor agonists slow gastric emptying and directly act on the GI tract — which is why nausea, vomiting, constipation, and diarrhoea are among the most commonly reported side effects, especially during dose escalation. For patients who already carry subclinical gut inflammation, the added pharmacological load on the intestinal lining can translate into meaningful discomfort and compromised nutrient absorption during a period when dietary intake is already significantly reduced.

Chronic Inflammation Does Not Resolve Automatically

Obesity and metabolic dysfunction are deeply inflammatory states. Chronic inflammation is a well-established driver of both metabolic dysfunction and impaired tissue repair. Losing weight reduces the inflammatory burden — but the timeline is nonlinear, and the pathways that drive inflammation (particularly NF-κB signalling) do not simply switch off as body fat declines. Patients on GLP-1 therapy often remain in a low-grade inflammatory state during the active weight loss phase, which can slow the very tissue remodelling that would otherwise benefit from reduced adiposity.

For a deeper look at how inflammation intersects with metabolic health, see our article on biomarkers that predict metabolic disease before symptoms appear.

The KLOW Peptides: What the Research Shows, Component by Component

GHK-Cu: The Collagen Signal

GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper) is a naturally occurring tripeptide found in human blood plasma. It was first isolated in 1973 and has since accumulated one of the more robust preclinical evidence bases of any peptide in regenerative medicine.

Key mechanisms:

• Stimulates collagen and elastin synthesis in fibroblasts at concentrations as low as 1 nanomolar
• Modulates expression of at least 4,000 genes, including pathways governing DNA repair and antioxidant defence
• Attracts immune and endothelial cells to sites of tissue injury
• Promotes angiogenesis (new blood vessel formation) essential to delivering the nutrient supply that skin remodelling requires

The evidence: A foundational peer-reviewed study in BioMed Research International confirmed that GHK-Cu stimulates both collagen synthesis and breakdown simultaneously — functioning not as a crude growth signal but as a regulator of the full extracellular matrix remodelling cycle. A 2025 comprehensive review in Medical Science Monitor covering studies from 2016–2025 confirmed that GHK-Cu-based formulations enhance fibroblast migration, ECM remodelling, collagen and elastin synthesis, and wound closure across multiple model types.

Why it matters for GLP-1 users: GHK-Cu levels decline with age, reducing the body's baseline signal for tissue repair at exactly the moment GLP-1-driven weight loss is placing the greatest demand on it. The GHK-Cu component of KLOW is, mechanistically, the primary counter to the collagen depletion and skin laxity that patients experience as "Ozempic face."

GHK-Cu is also the component with the longest track record in topical form — it is an FDA-approved cosmetic ingredient. Its use in injectable compounded form, however, is a separate regulatory category, and patients should confirm sourcing and clinical oversight before use.

BPC-157: The Gut and Tissue Repair Engine

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino acid peptide derived from a protein found in human gastric juice. It is the component of KLOW with the greatest relevance to GLP-1 users experiencing gastrointestinal side effects.

Key mechanisms:

• Promotes healing of mucosal tissue throughout the GI tract — oesophagus, stomach, duodenum, and lower intestine
• Stimulates angiogenesis through VEGF and other growth factor pathways
• Accelerates repair of tendons, ligaments, and muscle via fibroblast activation
• Modulates the nitric oxide pathway to restore microvascular integrity

The evidence: A 2026 peer-reviewed article in the International Journal of Molecular Sciences summarised BPC-157's reparative properties across diverse preclinical models, noting consistent evidence for gastrointestinal healing, angiogenesis, and tendon and ligament repair. An earlier review in Frontiers in Pharmacology documented BPC-157's successful application across incisional wounds, deep burns, diabetic ulcers, and intestinal anastomoses — all at the same dose range and via multiple routes, a consistency that speaks to its mechanism's robustness. For GI-specific applications, BPC-157 has been studied in two human trials for ulcerative colitis and multiple sclerosis, with no reported toxicity and an LD1 (lethal dose) that was never achieved in preclinical models.

Why it matters for GLP-1 users: BPC-157's GI mucosal protection is arguably the most immediately relevant benefit for anyone experiencing the nausea, reflux, and GI motility disruption common during GLP-1 dose escalation. Additionally, its angiogenic effect ensures that wherever KLOW's other peptides signal for repair, BPC-157 works to ensure that blood supply — and therefore nutrient delivery — reaches the target tissue.

KPV: The Inflammation Switch

KPV (Lysine-Proline-Valine) is a tripeptide — three amino acids — derived from the C-terminal sequence of alpha-melanocyte-stimulating hormone (α-MSH). It retains α-MSH's anti-inflammatory activity without its pigmentation-driving effects.

Key mechanisms:

• Directly inhibits NF-κB — the central transcription factor governing the body's inflammatory cascade
• Suppresses MAP kinase signalling pathways
• Reduces pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6
• Acts via PepT1 transporters in intestinal epithelial and immune cells, targeting gut-resident inflammation at the tissue level

The evidence: A landmark study published in Gastroenterology demonstrated that nanomolar concentrations of KPV inhibit NF-κB and MAP kinase inflammatory pathways and reduce pro-inflammatory cytokine secretion — and that oral administration of KPV reduces the incidence of chemically induced colitis in mice as measured by both histology and cytokine expression. A separate study in Molecular Therapy confirmed that KPV loaded into targeted nanoparticles accelerated mucosal healing and reduced inflammation in ulcerative colitis models through combined mechanisms.

Why it matters for GLP-1 users: Chronic NF-κB-driven inflammation is one of the principal barriers to the tissue remodelling that GLP-1 users need for skin and muscle recovery. KPV's role in KLOW is to reduce the inflammatory signalling that would otherwise blunt the collagen synthesis signals from GHK-Cu and the repair signals from BPC-157. It is also the component that makes KLOW more appropriate than GLOW for patients with reactive skin, gut inflammation, or systemic low-grade inflammatory burden — which describes a significant proportion of the metabolic health patient population.

TB-500: The Cell Migration Coordinator

TB-500 is a synthetic fragment of Thymosin Beta-4, a peptide involved in actin regulation and cellular movement. Its role in KLOW is architectural: it coordinates how repair cells move and organise at sites of tissue remodelling.

Key mechanisms:

• Regulates actin polymerisation, controlling how cells move and restructure tissue
• Promotes cell migration to sites of injury (fibroblasts, endothelial cells, keratinocytes)
• Biases healing toward functional tissue formation rather than scar tissue
• Supports angiogenesis and is documented to promote cardiac, corneal, and dermal wound healing in preclinical models

Why it matters for GLP-1 users: Skin that is remodelling under GHK-Cu stimulation and inflammation that is resolving under KPV suppression still requires cells to physically migrate to the remodelling site and organise correctly. Without adequate TB-500 signal, healing can occur disproportionately — favouring scar-like type III collagen over structural type I collagen. In the context of GLP-1-driven skin laxity, TB-500 is the component responsible for ensuring that new collagen deposits are organised, not merely present.

The Synergy Rationale: Why the Stack, Not Individual Peptides

The biological logic of KLOW is systems-based. Individual peptides address single mechanisms. The conditions that develop during GLP-1-driven weight loss are multi-mechanism problems:

• Collagen depletion is both a deficiency of synthesis signal (GHK-Cu) and a failure of cellular organisation (TB-500)
• GI disruption is both a mucosal injury (BPC-157) and an inflammatory state (KPV)
• Skin laxity is driven by structural loss, inflammatory burden, and inadequate repair signalling — all simultaneously

The stack is designed so that each component removes a bottleneck that would otherwise limit the effectiveness of the others. BPC-157's angiogenic effect ensures the vascular supply for GHK-Cu's collagen signal. KPV's NF-κB suppression reduces the inflammatory interference that would blunt both. TB-500 coordinates the cell migration required to act on those signals.

As one clinical overview at Revolution Health & Wellness describes it: the combination allows tissues to heal faster and more completely than any single peptide could accomplish — because each bottleneck in the repair cascade is being addressed simultaneously.

What the Clinical Evidence Honestly Does Not Yet Show

Intellectual honesty requires stating plainly what the research base does not support:

No randomised controlled trial exists for the KLOW stack as a combined formulation. The evidence for each individual peptide is real and, in some cases (particularly GHK-Cu and KPV), published in peer-reviewed journals of high standing. But no clinical trial has examined the safety or efficacy of the four-peptide combination as administered. Synergy is theoretically compelling; it has not been empirically measured in humans.

Most BPC-157 and TB-500 data is preclinical. Human trials for BPC-157 are limited to small pilot studies. TB-500 human data is primarily from ophthalmic applications (RGN-259 and RGN-137, which use full-length Thymosin Beta-4, not the TB-500 fragment). The translational gap between animal models and human outcomes for these two peptides remains significant.

GHK-Cu injectable data differs from topical data. GHK-Cu's topical evidence base is substantially more robust than its injectable evidence base. The assumption that injectable bioavailability produces superior outcomes to what topical studies show is mechanistically plausible but not directly confirmed in controlled human trials.

KLOW has not been specifically studied in GLP-1 users. The application of KLOW to the GLP-1 weight loss context is a clinically reasoned extension of each peptide's individual mechanism — not a validated protocol backed by trials in this population. The combination of Retatrutide and KLOW is emerging as a patient-reported protocol, but clinical literature on this specific pairing does not exist as of mid-2026.

This is not an argument against KLOW. It is an argument for having the conversation with a physician who is familiar with both the peptide literature and your full clinical picture, rather than self-prescribing based on forum consensus. See our article on peptide therapy entering mainstream medicine — what the evidence base looks like in 2025 for broader context on how to evaluate peptide protocols.

Who Is a Candidate for KLOW During GLP-1 Therapy?

Based on the mechanism of each component, the patients most likely to benefit from exploring KLOW with their physician are those who:

• Are actively on a GLP-1 receptor agonist (semaglutide, tirzepatide, retatrutide) and losing weight at a rate of 1–2+ lb/week
• Are experiencing visible skin laxity, facial volume loss, or skin texture changes as weight declines
• Have significant GI side effects (nausea, diarrhoea, mucosal discomfort) during dose escalation
• Carry known markers of systemic inflammation — elevated hsCRP, elevated fasting insulin, or other metabolic biomarkers that have been flagged in prior lab work
• Are in their 40s or older, where baseline collagen decline makes the gap between demand and capacity most acute
• Have a history of inflammatory bowel conditions, slow wound healing, or joint/soft tissue injuries that have not fully resolved

KLOW is less likely to be the primary tool for patients who are early in GLP-1 therapy, losing weight slowly, have no skin or GI symptoms, and carry no background inflammatory burden.

For a full picture of what to measure before and during GLP-1 therapy, see our complete GLP-1 FAQ and our guide on lab work questions to ask your physician at each GLP-1 visit.

KLOW and Metabolic Health: The Inflammation Link

There is a dimension of KLOW's mechanism that is particularly relevant to Meto's patient population and is rarely discussed in peptide-focused content.

Metabolic dysfunction — insulin resistance, visceral adiposity, elevated fasting glucose — does not exist in isolation from systemic inflammation. The two are deeply intertwined. Adipose tissue in metabolic disease is itself an inflammatory organ, secreting cytokines (adipokines) that sustain the NF-κB-driven inflammatory state that makes insulin resistance self-perpetuating.

When GLP-1 therapy begins resolving the adiposity, the inflammatory burden should begin to resolve with it. But this is not instantaneous — and during the transition, patients are often in a state where the metabolic disease is receding but the inflammatory infrastructure that supported it is still partially active.

KPV's NF-κB inhibition during this transition period is not merely a skin or gut benefit. It is, mechanistically, a direct intervention on the same signalling pathway that underlies the metabolic inflammation that made weight loss difficult in the first place. This is the intersection that makes KLOW particularly interesting from a metabolic medicine perspective — not just as a recovery support tool but as a potential complementary intervention in the inflammatory phase of metabolic disease reversal.

This intersection of inflammation and metabolic health is explored in depth in our article on metabolic health versus weight loss: why the distinction matters clinically.

Practical Considerations: What to Discuss with Your Physician

If you are considering KLOW as part of your GLP-1 protocol, these are the questions your physician will need to help you work through:

Sourcing and compounding quality. KLOW is not a standardised pharmaceutical. Vial composition, peptide purity, and third-party testing vary significantly between compounding pharmacies. Your physician should be able to identify a supplier with documented batch-level certificates of analysis.

Timing and cycling. The general research-community protocols describe daily subcutaneous injection for 8–12 weeks, with dose titration in the first weeks to assess tolerance. Some practitioners cycle KLOW during periods of rapid weight loss and discontinue during maintenance phases. Your physician should factor in your rate of weight loss and symptom burden when recommending a cycle structure.

Contraindications and monitoring. Because no long-term human safety data exists for the stack as a combined formulation, patients with active malignancy, autoimmune disease under immunosuppression, or pregnancy should discuss KLOW with particular care. Routine inflammatory markers (hsCRP, ferritin) and skin/symptom monitoring provide useful clinical checkpoints during a KLOW protocol.

Adjunct support. KLOW does not replace the foundational pillars of metabolic recovery: adequate protein intake (to preserve lean mass), resistance training (to maintain the musculature that gives skin its underlying structure), and sleep (where the majority of tissue repair occurs). The evidence for GHK-Cu's collagen signalling, for example, is strongest when the cellular energy and nutrient supply required for collagen synthesis are not rate-limiting — which means KLOW works best as a tool layered on top of, not instead of, sound metabolic nutrition.

Frequently Asked Questions

What is the KLOW peptide stack? 

KLOW is a compounded four-peptide blend containing GHK-Cu (50 mg), BPC-157 (10 mg), TB-500 (10 mg), and KPV (10 mg). It is designed to address inflammation, tissue repair, collagen synthesis, and cellular remodelling through complementary biological mechanisms.

How is KLOW different from GLOW? 

GLOW contains three peptides: GHK-Cu, BPC-157, and TB-500. KLOW adds KPV, a potent anti-inflammatory tripeptide that inhibits NF-κB signalling. KLOW is the more appropriate stack for patients with active inflammation, reactive skin, GI distress, or chronic inflammatory burden.

Can I take KLOW while on semaglutide or tirzepatide? 

KLOW and GLP-1 receptor agonists operate through completely separate receptor systems with no known pharmacological interaction. The combination is being used clinically and reported anecdotally in the research community. However, as with all adjunct interventions during GLP-1 therapy, this should be evaluated and supervised by a qualified physician.

Is KLOW FDA-approved? 

No. KLOW is a compounded preparation, not an FDA-approved drug product. Individual components of KLOW have varying regulatory statuses — GHK-Cu, for example, is FDA-approved for topical cosmetic use but not for injection. The stack as a combined injectable formulation is outside the scope of FDA approval.

What does KLOW do for skin laxity from GLP-1 weight loss? 

The GHK-Cu component signals fibroblasts to produce new collagen and elastin. TB-500 coordinates cell migration to ensure that repair cells organise at the remodelling site. KPV suppresses the NF-κB-driven inflammation that would blunt these signals. The combined effect is a multi-mechanism approach to the structural skin changes associated with rapid GLP-1 weight loss — though controlled trials specifically in GLP-1 users do not yet exist.

How long does KLOW take to work? 

Based on the known mechanisms of its components, clinical observers typically describe early texture changes within 2–4 weeks, improvements in fine lines and skin quality by 4–8 weeks, and structural remodelling and scar improvement by 8–12 weeks. These timelines are derived from individual peptide research and clinical practitioner observations, not from KLOW-specific controlled trials.

What are the side effects of KLOW? 

Individual peptides in KLOW have generally favourable safety profiles in preclinical research. Common reports from clinical use include mild injection-site irritation, a brief stinging sensation (attributable to the copper complex in GHK-Cu), and occasional temporary fatigue in the first week. No major adverse effects have been documented in the research literature for the individual components at the doses used in KLOW. No long-term safety data exists for the four-peptide combination.

The Bottom Line

KLOW represents a biologically coherent approach to the tissue-level consequences of GLP-1-driven weight loss. Each of its four components has a mechanistic rationale grounded in peer-reviewed research. The combination is designed to address the full repair cascade — not just one piece of it — and the inflammatory and GI-related components make it particularly relevant for the metabolic health patient on a GLP-1 protocol.

What KLOW is not is a validated clinical protocol backed by randomised controlled human trials. Patients should approach it as an emerging, physician-supervised complementary tool — one with an evidence-supported rationale but still-developing clinical literature.

If you are experiencing the downstream tissue effects of GLP-1 therapy — skin laxity, persistent GI disruption, slow recovery, chronic inflammation — it is worth asking whether your current protocol is addressing the biological cost of the weight loss, not just the weight loss itself.

That conversation starts with your physician.

This article is for educational purposes only and does not constitute medical advice. KLOW and the individual peptides it contains are not FDA-approved for the treatment of any disease. Always consult a qualified physician before beginning any peptide protocol, particularly during active pharmacological weight loss therapy.

Meto is a physician-led metabolic health platform. Our content is written and reviewed by clinicians with expertise in metabolic medicine, endocrinology, and evidence-based nutrition.